A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

Other illness

• Cognitive impairment due to other medical or neurological factors (non-AD).
• History of stroke or transient ischemic attack, seizures, or other unexplained loss of consciousness within the past 1 year.
• Any psychiatric diagnosis that may interfere with the subject's cognitive assessment.

Lab values

• Inability to tolerate MRI examination or have contraindications to MRI examination.
  • 6\. Exclusion criteria related to previous or concomitant diseases, as listed in the protocol.
  • 7\. Exclusion criteria related to general or laboratory tests, as listed in the protocol.
  • 8\. The subject is suicidal according to the investigator's judgment or has committed suicidal behaviour within 6 months prior to the screening period.
  • 9\. Severe visual or hearing impairment, unable to cooperate in the scale examination.
  • 10\. Patients suspected to be allergic to Aβ antibody drugs and their excipients.
  • 11\. Women who are pregnant, or women of childbearing age with positive pregnancy test results or are lactating.
  • 12\. History of drug abuse and/or drug addiction within 1 year prior to screening.
  • 13 Use of dual antiplatelet or anticoagulant drugs within 3 months prior to the randomization period or planned during the trial.
  • 14.Have had prior treatment with an anti-amyloid immunotherapy within 1 year prior to randomization.
  • 15\. Those who have participated in a clinical trial of any drug or medical device within 3 months prior to screening.
  • 16\. Investigators and site-related personnel or other persons directly involved in the implementation of the protocol.
  • 17\. Other unspecified reasons that, in the opinion of the investigator or sponsor, make the subject unsuitable for enrolment.

• Ability to understand the trial procedures and possible adverse events, voluntarily participate in the trial,
• Male or female aged between 55 years and 85 years (inclusive) at the date of signed consent form.
• Total body weight of 45\~100 kg (inclusive), with a body mass index (BMI) of 19\~32 kg/m2 (inclusive)at screening or baseline.
• The subjects must meet the following clinical criteria for Mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or criteria for mild AD.
• The subjects should have a stable caregiver who will help the patients to participate in the whole study process.